The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Open accessAbstract
In December 2005, sorafenib became the first new treatment to be approved for advanced renal cancer in more than a decade. Wilhelm and colleagues provide the history of this drug, which inhibits several kinases involved in tumour signalling and angiogenesis. Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) — from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 — was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedThe Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
CELLULAR ONCOGENES AND RETROVIRUSES
Bishop, J. M. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.001505 · Cited by 1,641
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Self-citationHuman EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Self-citationPrognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
c-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · cited 1×
“, or non-receptor tyrosine kinases (for example, Src”
BackgroundThe Fos family of transcription factors and their role in tumourigenesis
Milde-Langosch, K. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.008 · Cited by 583
Varmus, H. (1988) · Science · doi:10.1126/science.3287617 · Cited by 523
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Self-citationSmith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus
Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R. L., Isacke, C. M., Verma, I. M., & Ullrich, A. (1986) · Nature · doi:10.1038/320277a0 · Cited by 447
Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 443
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
Self-citation高橋, 敦. (1994) · Medical Entomology and Zoology · doi:10.11501/3101325 · Cited by 352
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
Self-citationMutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1
O'Neill, E., Rushworth, L., Baccarini, M., & Kolch, W. (2004) · Science · doi:10.1126/science.1103233 · Cited by 317
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
Self-citationTreatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.
Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., & Yoshida, O. (1995) · PubMed · Cited by 299
Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
Self-citationTakahashi, A., Sasaki, H., Kim, S. J., Tobisu, K.-I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., & Terada, M. (1994) · PubMed · Cited by 275
Salvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
The KRAS oncogene: Past, present, and future
Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.10.001 · Cited by 252
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522758 · Cited by 242
Dowell, J., Minna, J. D., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1612 · Cited by 219
Gallo, R., & Wong-Staal, F. (1982) · Blood · doi:10.1182/blood.v60.3.545.545 · Cited by 207
Epidermal growth factor and its receptor
Gill, G. N., Bertics, P. J., & Santon, J. B. (1987) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(87)90027-x · Cited by 195
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
Siu, L. L., Awada, A., Takimoto, C. H., Piccart, M., Schwartz, B., Giannaris, T., Lathia, C., Petrenciuc, O., & Moore, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1571 · Cited by 188
Self-citationBRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Salvatore, G., De Falco, V., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 172
Self-citationCancer therapeutics: Targeting the dark side of Myc
Ponzielli, R., Katz, S., Barsyte-Lovejoy, D., & Penn, L. Z. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.017 · Cited by 168
Strumberg, D., Awada, A. H., Hirte, H. W., Clark, J. W., Seeber, S., Piccart, P., Hofstra, E., Voliotis, D., Christensen, O., Brueckner, A., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.014 · Cited by 150
Self-citationDesign and Discovery of Small Molecules Targeting Raf-1 Kinase
Lowinger, T. B., Riedl, B., Dumas, J., & Smith, R. A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 150
Self-citationOver-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1
Hwang, Y. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.02.009 · Cited by 143
Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., Christensen, O., Brendel, E., Schwartz, B. E., Ludwig, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl017 · Cited by 142
Self-citationThe Molecular Basis of Oncogenes and Tumor Suppressor Genes
Weinberg, R. A. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb24838.x · Cited by 141
Abdel‐Rahman, M. H., Yang, Y., Zhou, X.-P., Craig, E. L., Davidorf, F. H., & Eng, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2418 · Cited by 129
The RET proto‐oncogene: A molecular therapeutic target in thyroid cancer
Kodama, Y., Asai, N., Kawai, K., Jijiwa, M., Murakumo, Y., Ichihara, M., & Takahashi, M. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00023.x · Cited by 119
Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses
Spector, D. H., Smith, K., Padgett, T., McCombe, P., Roulland-Dussoix, D., Moscovici, C., VARMUS, H. E., & Bishop, J. M. (1978) · Cell · doi:10.1016/0092-8674(78)90205-2 · Cited by 111
Clinical trials referral resource.
Cheson, B. D., Abrams, J., McCabe, M. S., & Crosson, K. (1990) · PubMed · Cited by 94
The role of Raf kinases in malignant transformation
Kölch, W., Kotwaliwale, A., Vass, K., & Janosch, P. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399402004386 · Cited by 91
On a possible epigenetic mechanism(s) of tumor cell heterogeneity: The role of DNA methylation
Frost, P., & Kerbel, R. S. (1983) · Cancer and Metastasis Reviews · doi:10.1007/bf00048568 · Cited by 86
FLT-3: a new focus in the understanding of acute leukemia
Marković, A. K., MacKenzie, K. L., & Lock, R. B. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.12.005 · Cited by 73
McDonald, O. B., Chen, W. J., Ellis, B., Hoffman, C. R., Overton, L. K., Rink, M., Smith, A., Marshalland, C. J., & Wood, E. R. (1999) · Analytical Biochemistry · doi:10.1006/abio.1998.3030 · Cited by 68
RAF antisense oligonucleotide as a tumor radiosensitizer
Kasid, U. N., & Dritschilo, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206700 · Cited by 50
Flaherty, K. T., Redlinger, M., Schuchter, L. M., Lathia, C. D., Weber, B., & O'Dwyer, P. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3037 · Cited by 50
Deregulated Repression of c-Jun Provides a Potential Link to its Role in Tumorigenesis
Weiß, C., & Bohmann, D. (2004) · Cell Cycle · doi:10.4161/cc.3.2.648 · Cited by 49
Raf‐1 expression may influence progression to androgen insensitive prostate cancer
Mukherjee, R., Bartlett, J. M. S., Krishna, N. S., Underwood, M. A., & Edwards, J. (2005) · The Prostate · doi:10.1002/pros.20211 · Cited by 48
Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Annunziata, C. M., Barrett, T., Premkumar, A., Kotz, H. L., Sarosy, G., Minasian, L. M., & Kohn, E. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3004 · Cited by 42
Finding the needle in the haystack: why high-throughput screening is good for your health
Aherne, G. W., McDonald, E., & Workman, P. (2002) · Breast Cancer Research · doi:10.1186/bcr440 · Cited by 36
Kloos, R. T., Ringel, M. D., Knopp, M. V., Heverhagen, J. T., Rittenberry, J., Weldy, L., Arbogast, D., Collamore, M., King, M., Young, D. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5534 · Cited by 30
Oncogenes as Novel Targets for Cancer Therapy (Part I): Growth Factors and Protein Tyrosine Kinases
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505030-00004 · Cited by 25
Oncogenes as Novel Targets for Cancer Therapy (Part IV): Regulators of the Cell Cycle and Apoptosis
Zhang, Z., Li, M., Rayburn, E. R., Hill, D. L., Zhang, R., & Wang, H. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505060-00006 · Cited by 21
Research works printed but not linked: 27
- Niman, H. L. Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor. Nature 307, 180–183 (1984). · doi:10.1038/307180a0
- McPhillips, F. et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer 85, 1753–1758 (2001). · doi:10.1054/bjoc.2001.2139
- Riedl, B. et al. Potent Raf kinase inhibitors from the diphenylurea class: structure activity relationships. Clin. Cancer Res. 20, 83a (2001).
- Smith, R. A. et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 11, 2775–2778 (2001). · doi:10.1016/s0960-894x(01)00571-6
- Wilhelm, S. et al. BAY 43-9006, a novel Raf-1 kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc. Am. Assoc. Cancer Res. 42, 923 (2001).
- Chang, Y. S. et al. BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Clin. Cancer Res. 46, 5831 (2005).
- Liu, L. et al. Sorafenib (BAY 43-9006) inhibits the Raf/MEK/ERK pathway in hepatocellular carcinoma (HCC) cells and produces robust efficacy against PLC/PRF/5 HCC tumors in mice. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Kupsch, P. et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5, 188–196 (2005). · doi:10.3816/ccc.2005.n.030
- Flaherty, K. T. et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus B-Raf status. Proc. 4th Intl. Symp. Targeted Anticancer Ther. Amsterdam, The Netherlands [online] , (2006).
- Awada, A. et al. A Phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with Taxotere in patients with advanced solid tumors. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Geneva, Switzerland (2004).
- Steinbild, S. et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J. Clin. Oncol. 23, 3115 (2005). · doi:10.1200/jco.2005.23.16_suppl.3115
- Eisen, T. et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol. 23, 7508 (2005). · doi:10.1200/jco.2005.23.16_suppl.7508
- Gollob, J. et al. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma. Eur. J. Cancer Supplements 3, 226 (2005).
- Robert, C. et al. Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur. J. Cancer Supplements 3, 254 (2005).
- Escudier, B. et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3, 226 (2005). Pivotal Phase III trial confirming sorafenib's significant PFS benefit and acceptable tolerability in patients with advanced refractory RCC. These findings formed the basis of sorafenib's recent FDA approval for this indication.
- Abou-Alfa, G. K. et al. Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Gatzemeier, U. et al. Phase II trial of single-agent sorafenib in patients with advanced non-small-cell lung carcinoma. J. Clin. Oncol. 24, 364s (2006). · doi:10.1200/jco.2006.24.18_suppl.7002
- Steinbild, S. et al. Phase II study of sorafenib (BAY43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research — EWIV (CESAR). J. Clin. Oncol. 24, 144s (2006). · doi:10.1200/jco.2006.24.18_suppl.3094
- Dahut, W. L. et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J. Clin. Oncol. 24, 218s (2006). · doi:10.1200/jco.2006.24.18_suppl.4506
- Moreno-Aspitia, A. et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J. Clin. Oncol. 24, 577 (2006). · doi:10.1200/jco.2006.24.18_suppl.577
- Lorigan, P. et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J. Clin. Oncol. 24, 8012 (2006). · doi:10.1200/jco.2006.24.18_suppl.8012
- Sosman, J. et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J. Clin. Oncol. 24, 128s (2006). · doi:10.1200/jco.2006.24.18_suppl.3031
- Elting, J. et al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 47, A2909 (2006).
- Advani, A. S. C-kit as a target in the treatment of acute myelogenous leukemia. Curr. Hematol. Rep. 4, 51–58 (2005).
- Chen, L. L. et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 7, 293–299 (2005). · doi:10.1007/s11912-005-0053-6
- Blumenschein, G. R. et al. Phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in relapsed or refractory advanced non-small cell lung cancer. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
- Levy, J. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res. 47, 213–214 (2006).
Cited by
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088
Yang, W. S., & Stockwell, B. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.010 · Cited by 1,876
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Metadata
- Authors
- Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-10-01
- Volume
- 5
- Issue
- 10
- Pages
- 835-844
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2061345986
- Cited by
- 1,829
- References
- 69
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.